Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JYS4
- Development stage
- Preclinical
- Lead developer
- Jiuyuan Gene Engineering
- Modality
- Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
JYS4 is a Class 1 new biologic drug developed by Hangzhou Jiuyuan Genetic Biopharmaceutical for the treatment of obesity and overweight. It is characterized as a polyclonal antibody, a modality that distinguishes it from many other weight-loss biologics typically focused on monoclonal antibodies or peptides. The drug received Investigational New Drug (IND) approval from the Chinese National Medical Products Administration (NMPA) in the fourth quarter of 2021. While the specific molecular target has not been publicly disclosed in company pipeline documents, it represents a novel therapeutic candidate within the developer's metabolic disease portfolio.
Beyond the preview
Go deeper on JYS4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JYS4.